Tumor-informed circulating tumor DNA (ctDNA) has shown promise as a biomarker for treatment response monitoring (TRM) in a variety of tumor types, with the potential to improve clinical outcomes. We ...
Rising Cancer Incidence Boosts Demand for Circulating Tumor Cell DetectionThe Circulating Tumor Cells (CTCs) market has ...
Circulating tumor DNA (ctDNA), small pieces of DNA released from dying tumor cells into the bloodstream, can be easily and non-invasively identified and examined through a simple blood test. This ...
Serum tumor markers (STMs), including alpha-fetoprotein (AFP) and human chorionic gonadotropin (hCG), are currently used in management of patients with germ cell tumors (GCTs). STMs in a substantial ...
Signatera can detect tumor DNA in the bloodstream. A new blood test seeks to change the game in cancer management. Signatera, a "tumor-informed" blood test developed by Natera, can detect circulating ...
A study led by scientists at NYU Langone Health and its Perlmutter Cancer Center has shown that monitoring blood levels of DNA fragments shed by dying tumor cells may accurately predict skin cancer ...
SECAUCUS, N.J., Aug. 25, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that the U.S. Food and Drug Administration (FDA) has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback